CN117046460A - Coating process applied to bilirubin adsorbent - Google Patents
Coating process applied to bilirubin adsorbent Download PDFInfo
- Publication number
- CN117046460A CN117046460A CN202310998951.1A CN202310998951A CN117046460A CN 117046460 A CN117046460 A CN 117046460A CN 202310998951 A CN202310998951 A CN 202310998951A CN 117046460 A CN117046460 A CN 117046460A
- Authority
- CN
- China
- Prior art keywords
- bilirubin
- chitosan
- adsorbent
- concentration
- coating process
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 title claims abstract description 118
- 239000003463 adsorbent Substances 0.000 title claims abstract description 52
- 238000000576 coating method Methods 0.000 title claims abstract description 20
- 229920001661 Chitosan Polymers 0.000 claims abstract description 47
- 238000003756 stirring Methods 0.000 claims abstract description 16
- 239000002253 acid Substances 0.000 claims abstract description 8
- 238000001914 filtration Methods 0.000 claims abstract description 8
- 238000002156 mixing Methods 0.000 claims abstract description 8
- 230000003472 neutralizing effect Effects 0.000 claims abstract description 8
- 238000001291 vacuum drying Methods 0.000 claims abstract description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000003513 alkali Substances 0.000 claims abstract description 5
- 239000003957 anion exchange resin Substances 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 10
- 239000002585 base Substances 0.000 claims description 9
- 150000007522 mineralic acids Chemical class 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 claims description 2
- 235000005985 organic acids Nutrition 0.000 claims 1
- 238000001179 sorption measurement Methods 0.000 abstract description 21
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 abstract description 5
- 239000011248 coating agent Substances 0.000 abstract description 4
- 239000000463 material Substances 0.000 abstract description 4
- 239000000243 solution Substances 0.000 description 23
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 235000013305 food Nutrition 0.000 description 8
- 241001646851 Coleus Species 0.000 description 5
- 235000021508 Coleus Nutrition 0.000 description 5
- 239000011347 resin Substances 0.000 description 5
- 229920005989 resin Polymers 0.000 description 5
- 239000008215 water for injection Substances 0.000 description 5
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 230000010355 oscillation Effects 0.000 description 2
- 238000011056 performance test Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 description 1
- CHRJZRDFSQHIFI-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;styrene Chemical compound C=CC1=CC=CC=C1.C=CC1=CC=CC=C1C=C CHRJZRDFSQHIFI-UHFFFAOYSA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 238000002617 apheresis Methods 0.000 description 1
- 208000027119 bilirubin metabolic disease Diseases 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- OHJMTUPIZMNBFR-UHFFFAOYSA-N biuret Chemical compound NC(=O)NC(N)=O OHJMTUPIZMNBFR-UHFFFAOYSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000001951 hemoperfusion Effects 0.000 description 1
- 208000036796 hyperbilirubinemia Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/745—Polymers of hydrocarbons
- A61K31/75—Polymers of hydrocarbons of ethene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/22—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
- B01J20/28002—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their physical properties
- B01J20/28011—Other properties, e.g. density, crush strength
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/3085—Chemical treatments not covered by groups B01J20/3007 - B01J20/3078
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Analytical Chemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a coating process applied to bilirubin adsorbent, which comprises the following steps: s1: dissolving chitosan in acid with a certain concentration to prepare chitosan solution with a certain concentration; s2: under the condition of stirring, adding the bilirubin adsorbent into the chitosan solution in the S1, and stirring for 3-7min; s3: filtering the stirred solution, vacuum drying at 55-65deg.C, mixing with injectable water, and neutralizing with alkali to neutrality to obtain bilirubin adsorbent coated with chitosan. According to the invention, chitosan is used as a coating material of the bilirubin adsorbent, so that the problem of potential safety hazard of the existing poly (hydroxyethyl methacrylate) film is solved, and the adsorption performance of the adsorbent on bilirubin is further improved.
Description
Technical Field
The invention relates to the technical field of blood purification, in particular to a coating process applied to bilirubin adsorbent.
Background
Bilirubin is a bioactive substance produced by catabolism of hemoglobin, about 250-300mg of bilirubin is produced in healthy adult human bodies every day, the production amount of bilirubin in newborns is higher, the liver and gall dysfunction can be caused by the excessive concentration of bilirubin in blood, permanent damage is caused to nervous systems and brains, and how to efficiently and timely remove excessive free bilirubin in blood is the core and key for clinically treating hyperbilirubinemia. Hemoperfusion therapy based on the adsorption principle is one of the effective methods for removing bilirubin, and its therapeutic effect depends on the performance of the adsorbent.
At present, the plasma bilirubin adsorbent which is clinically used is mainly styrene-divinylbenzene anion exchange resin, and is mainly because bilirubin is adsorbed by charge adsorption (BL-300 anion exchange resin (Therapeutic Apheresis and dialysis.2003,7 (1): 98-103) is represented in synthetic resin), the adsorption rate can reach 50-60 percent, and the adsorption effect is better than other adsorption modes. For example, there are some products in clinic, namely, a disposable bilirubin adsorption column uses anion exchange resin, and the problem of biocompatibility of the material is solved by physically coating polyhydroxyethyl methacrylate or modified polyvinyl alcohol on the surface of the anion exchange resin, wherein polyhydroxyethyl methacrylate is a more common coating material. However, the poly (hydroxyethyl methacrylate) film is a transparent soft film with viscosity, and unreacted hydroxyethyl methacrylate monomer remained in the film is difficult to thoroughly purify, which brings about potential safety hazard to clinical use, so that we propose an encapsulation process applied to bilirubin adsorbent.
Disclosure of Invention
Based on the technical problems existing in the background technology, the invention provides a coating process applied to bilirubin adsorbent.
The invention provides a coating process applied to bilirubin adsorbent, which comprises the following steps:
s1: dissolving chitosan in acid with a certain concentration to prepare chitosan solution with a certain concentration;
s2: under the condition of stirring, adding the bilirubin adsorbent into the chitosan solution in the S1, and stirring for 3-7min;
s3: filtering the stirred solution, vacuum drying at 55-65deg.C, mixing with injectable water, and neutralizing with alkali to neutrality to obtain bilirubin adsorbent coated with chitosan.
Preferably, in S1, the molecular weight of chitosan is not less than 25 kilodaltons.
Preferably, in S1, the acid is selected from organic acid and inorganic acid, preferably food grade hydrochloric acid, and the concentration of the acid is not lower than 1%, preferably 1%.
Preferably, in S3, the alkali is weak base or strong base, preferably food grade sodium hydroxide or sodium carbonate, sodium bicarbonate, etc.
Preferably, in S2, the bilirubin adsorbent may be selected from a strong basic anion exchange resin and a weak basic anion exchange resin, preferably a food grade strong basic anion exchange resin.
Preferably, in the step S1, the concentration of the chitosan solution is 0.1% -5%.
Preferably, the concentration of the chitosan solution is 0.5-3%.
Preferably, the chitosan solution has a concentration of 1%.
Compared with the prior art, the invention uses chitosan as the coating material of the bilirubin adsorbent, solves the potential safety hazard problem of the prior poly (hydroxyethyl methacrylate) membrane, and further improves the adsorption performance of the adsorbent on bilirubin.
Drawings
Fig. 1 shows a chemical molecular formula of chitosan used in the coating process of bilirubin adsorbent according to the present invention.
Detailed Description
The invention is further illustrated below in connection with specific embodiments.
Example 1
The embodiment provides a coating process applied to a bilirubin adsorbent, which comprises the following steps:
s1: chitosan with molecular weight not lower than 25 ten thousand daltons (molecular weight of 28kDa, medical grade, chemical molecular formula shown in figure 1) is dissolved in 1% food grade hydrochloric acid to prepare 0.5% chitosan solution;
s2: under the condition of stirring, adding the bilirubin adsorbent strong-base anion exchange resin (commercially available resin BL-300, purchased from Coleus company) into the chitosan solution in the S1 according to the volume ratio of 1:2, and stirring for 5min;
s3: filtering the stirred solution, vacuum drying at 60 ℃, mixing with water for injection according to the volume ratio of 1:2, and neutralizing to neutrality by using food-grade sodium hydroxide to obtain the bilirubin adsorbent coated with chitosan on the surface.
Example two
The embodiment provides a coating process applied to a bilirubin adsorbent, which comprises the following steps:
s1: chitosan with molecular weight not lower than 25 ten thousand daltons (molecular weight 48kDa, medical grade, zhejiang gold shell pharmaceutical Co., ltd.) is dissolved in acid with concentration not lower than 1% to prepare chitosan solution with concentration of 0.5%;
s2: under the condition of stirring, adding the bilirubin adsorbent strong-base anion exchange resin (commercially available resin BL-300, purchased from Coleus company) into the chitosan solution in the S1 according to the volume ratio of 1:2, and stirring for 5min;
s3: filtering the stirred solution, vacuum drying at 60 ℃, mixing with water for injection according to the volume ratio of 1:2, and neutralizing to neutrality by using food-grade sodium hydroxide to obtain the bilirubin adsorbent coated with chitosan on the surface.
Example III
The embodiment provides a coating process applied to a bilirubin adsorbent, which comprises the following steps:
s1: chitosan with molecular weight not lower than 25 ten thousand daltons (molecular weight 48kDa, medical grade, zhejiang gold shell pharmaceutical Co., ltd.) is dissolved in 1% concentration food grade hydrochloric acid to prepare 1% concentration chitosan solution;
s2: under the condition of stirring, adding the bilirubin adsorbent strong-base anion exchange resin (commercially available resin BL-300, purchased from Coleus company) into the chitosan solution in the S1 according to the volume ratio of 1:2, and stirring for 5min;
s3: filtering the stirred solution, vacuum drying at 60 ℃, mixing with water for injection according to the volume ratio of 1:2, and neutralizing to neutrality by using sodium hydroxide (food grade), thus obtaining the bilirubin adsorbent coated with chitosan on the surface.
Example IV
The embodiment provides a coating process applied to a bilirubin adsorbent, which comprises the following steps:
s1: chitosan with molecular weight not lower than 25 ten thousand daltons (molecular weight 48kDa, medical grade, zhejiang gold shell pharmaceutical Co., ltd.) is dissolved in 1% concentration food grade hydrochloric acid to prepare a 3% concentration chitosan solution;
s2: under the condition of stirring, adding the bilirubin adsorbent strong-base anion exchange resin (commercially available resin BL-300, purchased from Coleus company) into the chitosan solution in the S1 according to the volume ratio of 1:2, and stirring for 5min;
s3: filtering the stirred solution, vacuum drying at 60 ℃, mixing with water for injection according to the volume ratio of 1:2, and neutralizing to neutrality by using food-grade sodium hydroxide to obtain the bilirubin adsorbent coated with chitosan on the surface.
Example five
The embodiment provides a coating process applied to a bilirubin adsorbent, which comprises the following steps:
s1: chitosan with molecular weight not lower than 25 ten thousand daltons (molecular weight 48kDa, medical grade, zhejiang gold shell pharmaceutical Co., ltd.) is dissolved in 1% concentration food grade hydrochloric acid to prepare 5% concentration chitosan solution;
s2: under the condition of stirring, adding the bilirubin adsorbent strong-base anion exchange resin (commercially available resin BL-300, purchased from Coleus company) into the chitosan solution in the S1 according to the volume ratio of 1:2, and stirring for 5min;
s3: filtering the stirred solution, vacuum drying at 60 ℃, mixing with water for injection according to the volume ratio of 1:2, and neutralizing to neutrality by using food-grade sodium hydroxide to obtain the bilirubin adsorbent coated with chitosan on the surface.
The chitosan coated bilirubin adsorbent and the non-coated bilirubin adsorbent prepared in examples 1-5 above were used for evaluating the adsorption performance of plasma proteins, and the procedure was as follows:
carrying out in-vitro oscillation adsorption test by using common frozen plasma as adsorption solution according to the proportion of 20mg adsorbent and 20ml plasma, obtaining total protein content in the sample to be detected by using plasma after adsorption for 2 hours according to a biuret method, obtaining albumin content by using a BCG method, and obtaining the difference between total protein and albumin as the globulin content, wherein the results are shown in Table 1:
table 1 results of adsorption test of proteins by example and non-coated bilirubin adsorbent
From Table 1, it is clear that the adsorption rate of the three proteins of BL-300 bilirubin adsorbent coated with chitosan is obviously reduced, and meets the use requirements of blood purification products.
The chitosan coated bilirubin adsorbent and the non-coated bilirubin adsorbent prepared in examples 1-5 above adsorb bilirubin in liver disease positive plasma, and the procedure is as follows:
the plasma replaced during the plasma exchange treatment of liver disease patients is used as an adsorption solution, an in-vitro oscillation adsorption test is carried out according to the proportion of adding 10ml of plasma into 1ml of adsorbent, the concentration of bilirubin is detected by taking the plasma after 2 hours of adsorption, and the adsorption performance test results are shown in table 2:
table 2 results of the adsorption performance test of the example and non-coated bilirubin adsorbent
As is clear from Table 2, the BL-300 bilirubin adsorbent coated with chitosan can improve the effect of bilirubin adsorption, and the adsorption rate can be improved by more than 10% compared with the uncoated adsorbent.
The foregoing is only a preferred embodiment of the present invention, but the scope of the present invention is not limited thereto, and any person skilled in the art, who is within the scope of the present invention, should make equivalent substitutions or modifications according to the technical scheme of the present invention and the inventive concept thereof, and should be covered by the scope of the present invention.
Claims (8)
1. The coating process applied to the bilirubin adsorbent is characterized by comprising the following steps of:
s1: dissolving chitosan in acid with a certain concentration to prepare chitosan solution with a certain concentration;
s2: under the condition of stirring, adding the bilirubin adsorbent into the chitosan solution in the S1, and stirring for 3-7min;
s3: filtering the stirred solution, vacuum drying at 55-65deg.C, mixing with injectable water, and neutralizing with alkali to neutrality to obtain bilirubin adsorbent coated with chitosan.
2. The process of claim 1, wherein the molecular weight of chitosan in S1 is not less than 25 kilodaltons.
3. The process of claim 1, wherein the concentration of the acid in S1 is not less than 1% and the acid is selected from the group consisting of organic acids and inorganic acids.
4. The process of claim 1, wherein the alkali in S3 is a weak base or a strong base.
5. The process of claim 1, wherein in S2, the bilirubin adsorbent is selected from the group consisting of a strongly basic anion exchange resin and a weakly basic anion exchange resin.
6. The coating process for bilirubin adsorbents according to claim 1, wherein the concentration of chitosan solution in S1 is 0.1% -5%.
7. The coating process for bilirubin adsorbents according to claim 6, wherein the concentration of the chitosan solution is 0.5-3%.
8. The coating process for bilirubin adsorbents of claim 7 wherein the chitosan solution is at a concentration of 1%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310998951.1A CN117046460A (en) | 2023-08-09 | 2023-08-09 | Coating process applied to bilirubin adsorbent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310998951.1A CN117046460A (en) | 2023-08-09 | 2023-08-09 | Coating process applied to bilirubin adsorbent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117046460A true CN117046460A (en) | 2023-11-14 |
Family
ID=88660162
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310998951.1A Pending CN117046460A (en) | 2023-08-09 | 2023-08-09 | Coating process applied to bilirubin adsorbent |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117046460A (en) |
-
2023
- 2023-08-09 CN CN202310998951.1A patent/CN117046460A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE4239442C2 (en) | Use of an adsorbent material modified with polynuclear metal oxide hydroxides for the selective elimination of inorganic phosphate from protein-containing liquids | |
| CN106178161B (en) | Method for removing cytokines from blood using surface immobilized polysaccharides | |
| JP5774607B2 (en) | Removal of toxic factors by in vitro treatment | |
| WO2017174016A1 (en) | Medical macromolecular microsphere adsorbent for blood perfusion apparatus and manufacturing method thereof | |
| US4140652A (en) | Method of preparing blood-compatible sorbents for recovering exo- and endogenic poisons | |
| JPH0567305B2 (en) | ||
| CN108636374B (en) | Dopamine grafted sulfonated sodium alginate double-crosslinked microsphere and preparation method and application thereof | |
| CN1481907A (en) | Carboxymethyl chitosan / carboxymethyl cellulose operative antiblocking film and method for making the same | |
| CN109621912A (en) | A kind of coating method of blood perfusion acticarbon | |
| CN112871139B (en) | Whole blood perfusion adsorbent, preparation method and application thereof | |
| CN108031454A (en) | Possesses blood-purifying adsorbing agent of physics specific selectivity and preparation method thereof | |
| CN104693332A (en) | Glycosylated medical macroporous adsorption resin | |
| CN109692372B (en) | Five-layer blood perfusion device and blood perfusion method | |
| CN201669064U (en) | Anti-coagulation composite ultrafiltration membrane | |
| CN1289183C (en) | Method for preparing macromolecule resin type bilirubin sorbent | |
| CN117046460A (en) | Coating process applied to bilirubin adsorbent | |
| CN113426423B (en) | Adsorbent for removing LDL (low density lipoprotein) by extracorporeal blood circulation, preparation method thereof and perfusion device | |
| JPH0518625B2 (en) | ||
| CN111701580B (en) | Middle molecular toxin adsorbent for removing beta 2 microglobulin in blood | |
| CN1583245A (en) | Endotoxin adsorptive material, preparing and use thereof | |
| CN103301446A (en) | Affinity adsorption material for treating hyperbilirubinemia and preparation method thereof | |
| CN112876722A (en) | Traditional Chinese medicine coating for improving surface biocompatibility of medical instrument and preparation method thereof | |
| CN116492991B (en) | Method for preparing filling material of blood perfusion device capable of removing TNF-alpha in blood | |
| CN203139198U (en) | Simple blood purifier | |
| EP2753425B1 (en) | Use of modified hollow fiber materials for removing exotoxins produced by escherichia coli from blood and plasma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |